Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.
Morishima Y, Ogura M, Nishimura M, Yazaki F, Bessho M, Mizoguchi H, Chiba S, Hirai H, Tauchi T, Urabe A, Takahashi M, Ohnishi K, Yokozawa T, Emi N, Hirano M, Shimazaki C, Nakao S, Kawai Y, Fujimoto M, Taguchi H, Jinnai I, Ohno R. Morishima Y, et al. Among authors: emi n. Int J Hematol. 2004 Oct;80(3):261-6. doi: 10.1532/ijh97.04074. Int J Hematol. 2004. PMID: 15540902 Clinical Trial.
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.
Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R, Ohnishi K; Japan Adult Leukemia Study Group. Ono T, et al. Among authors: emi n. Leuk Res. 2011 May;35(5):598-603. doi: 10.1016/j.leukres.2010.12.006. Epub 2011 Jan 15. Leuk Res. 2011. PMID: 21239056
Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study.
Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K, Naoe T. Ishikawa Y, et al. Among authors: emi n. Cancer Sci. 2010 Oct;101(10):2186-92. doi: 10.1111/j.1349-7006.2010.01643.x. Epub 2010 Jul 1. Cancer Sci. 2010. PMID: 20608939 Free article.
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies.
Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K, Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi N, Kiyoi H, Miyazaki Y, Emi N, Kobayashi Y, Ohno R, Naoe T; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: emi n. Cancer. 2013 Sep 15;119(18):3326-33. doi: 10.1002/cncr.28212. Epub 2013 Jun 24. Cancer. 2013. PMID: 23798329 Free article. Clinical Trial.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: emi n. J Clin Oncol. 2006 Jan 20;24(3):460-6. doi: 10.1200/JCO.2005.03.2177. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344315 Clinical Trial.
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R; Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S, et al. Among authors: emi n. Cancer. 2005 Dec 15;104(12):2726-34. doi: 10.1002/cncr.21493. Cancer. 2005. PMID: 16284985 Free article. Clinical Trial.
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R. Sakamaki H, et al. Among authors: emi n. Int J Hematol. 2010 Mar;91(2):284-92. doi: 10.1007/s12185-009-0483-2. Int J Hematol. 2010. PMID: 20063133 Clinical Trial.
Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.
Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, Fujisawa S, Sakura T, Okumura H, Iriyama N, Emi N, Fujimaki K, Honda S, Miyazaki Y, Naoe T. Miyamura K, et al. Among authors: emi n. Blood Adv. 2019 Feb 12;3(3):312-319. doi: 10.1182/bloodadvances.2018025981. Blood Adv. 2019. PMID: 30705033 Free PMC article. Clinical Trial.
219 results